English

Interim report Q2, 2024: Strong Technologies growth and improved margins

Report this content

Second quarter

  • Sales of SEK 941 (905) million, an increase of 4% in local currencies and 4% in SEK.
  • Sales per region, in local currencies was -5% in APAC, +11% in EMEA and +5% in Americas.
  • Sales growth per business area, in local currencies, was +3% in Consumables, +40% in Technologies and -7% in Genetics.
  • Gross margin increased to 59.9% (55.8).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 327 (293) million, giving an EBITDA margin of 34.7% (32.4).
  • Operating cash flow increased to SEK 236 million (211).
  • Net income increased to SEK 143 (106) million, giving earnings per share of SEK 1.06 (0.78).
  • Vitrolife Group acquired the distribution activities of medical devices from EMB, our Iberian distributor.
  • Vitrolife Group acquired eFertility (STB Zorg B.V.).

First half year

  • Sales of SEK 1,782 (1,759) million, an increase of 2% in local currencies and 1% in SEK.
  • Sales per region, in local currencies was +6% in APAC, +4% in EMEA and -4% in Americas.
  • Sales per business area, in local currencies was +8% in Consumables, +23% in Technologies and -10% in Genetics.
  • Gross margin increased to 58.6% (56.3).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 600 (554) million, giving an EBITDA margin of 33.6% (31.5).
  • Operating cash flow increased to SEK 434 million (372).
  • Net income increased to SEK 258 (205) million, giving earnings per share of SEK 1.91 (1.52).
     

Gothenburg, July 17, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2024 08:00 CET.

Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_____________________________________________________________________________________________________________________________________________________________

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient’s fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden. 

Vitrolife Group’s products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to enable people to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

Subscribe

Documents & Links